## Lead generation of intramolecular glue stabilizer targeting CBL-B as a treatment of colorectal cancer

**IMMUSE Therapeutics** 

ONCOLOGY	Lead
Product Type	Other-TPD
Indication	Colorectal Cancer (MSI-H/dMMR)
Target	CBL-B
MOA(Mechanism of Action)	The intramolecular glue stabilizer is designed to enhance the anti-tumor immune response by specifically targeting the intracellular immune checkpoint (CBL-B) on exhausted T cells
Competitiveness	<ul> <li>Synergistic effect         <ul> <li>It is expected through combination with cell surface immune checkpoint inhibitors and intracellular modulator CBL-B molecular glue.</li> </ul> </li> <li>Potential for target market expansion         <ul> <li>It can be expanded to other cancer types</li> <li>It can also be applied as a version new payload od ADC</li> </ul> </li> </ul>
Development Stage	Discovery (Lead Identification)
Route of Administration	Oral administration

